VKTX
VIKING THERAPEUTICS, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $58 | $29 | -51% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $58 | $29 | -51% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $58 | $29 | -51% |
| AQR Capital Management re-entered | Q3 2024(8Q snapshot) | 7Q | $58 | $29 | -51% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $58 | $29 | -51% |
| Bridgewater Associates | Q4 2025 | 2Q | $39 | $29 | -26% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Soros Fund Management | Q1 2026 | Q2 2026 | → $30 | +4% |
| Point72 Asset Management 2× in & out | Q1 2026 | Q2 2026 | → $30 | -1% |
| Duquesne Family Office | Q3 2025 | Q4 2025 | → $39 | -2% |
| Renaissance Technologies 2× in & out | Q2 2025 | Q4 2025 | → $39 | +47% |
| Viking Global Investors | Q2 2023 | Q1 2025 | → $30 | +39% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Viking Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 3, 2026 — the most recent Form 4 on file — not from today.
- Form 40001193125-26-256039Jun 3, 2026
- Form 40001193125-26-100581Mar 10, 2026
- Form 40001193125-26-023030Jan 26, 2026
- Form 40001193125-26-003116Jan 5, 2026
- Form 40001193125-26-003115Jan 5, 2026
- Form 40001193125-26-003113Jan 5, 2026
- Form 40001193125-26-003112Jan 5, 2026
- Form 40001193125-26-003111Jan 5, 2026
- Form 40001193125-26-003110Jan 5, 2026
- Form 40001193125-26-003109Jan 5, 2026
- Form 40001193125-26-003108Jan 5, 2026
- Form 40001193125-25-254304Oct 28, 2025
- Form 40001193125-25-254300Oct 28, 2025
- Form 40001193125-25-254299Oct 28, 2025
- Form 40001193125-25-254298Oct 28, 2025
Fundamentals
XBRL · VIKING THERAPEUTICS, INC.Annual figures sourced directly from VIKING THERAPEUTICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Viking Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 26, 2026
- 10-QQuarterly reportApr 30, 2026
- 8-KMaterial eventApr 29, 2026
- DEF 14AProxy statementApr 1, 2026
- 10-KAnnual reportFeb 11, 2026
- 8-KMaterial eventFeb 11, 2026
- 10-QQuarterly reportOct 23, 2025
- 8-KMaterial eventOct 22, 2025
- 8-KMaterial eventAug 19, 2025
- 10-QQuarterly reportJul 23, 2025
- 8-KMaterial eventJul 23, 2025
- 8-KMaterial eventMay 27, 2025
- 10-QQuarterly reportApr 24, 2025
- 8-KMaterial eventApr 23, 2025
- 8-KMaterial eventApr 23, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| AQR Capital Management | Q2 2026 | open | $30 | $29 | -5% |
| Point72 Asset Management | Q1 2026 | Q2 2026 | $30 | $30 | -1% |
| Soros Fund Management | Q1 2026 | Q2 2026 | $29 | $30 | +4% |
| Bridgewater Associates | Q4 2025 | open | $39 | $30 | -24% |
| Duquesne Family Office | Q3 2025 | Q4 2025 | $40 | $39 | -2% |
| Point72 Asset Management | Q3 2025 | Q4 2025 | $40 | $39 | -3% |
| Two Sigma Investments | Q2 2025 | open | $27 | $29 | +5% |
| Renaissance Technologies | Q2 2025 | Q4 2025 | $27 | $39 | +47% |
| Citadel Advisors | Q3 2024 | open | $58 | $29 | -51% |
| Two Sigma Investments | Q3 2024 | Q1 2025 | $58 | $30 | -48% |
| D.E. Shaw | Q3 2024 | open | $58 | $29 | -51% |
| AQR Capital Management | Q3 2024 | Q1 2026 | $58 | $30 | -48% |
| Millennium Management | Q3 2024 | open | $58 | $29 | -51% |
| Renaissance Technologies | Q3 2024 | Q1 2025 | $57 | $30 | -48% |
| Viking Global Investors | Q2 2023 | Q1 2025 | $22 | $30 | +39% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.